title: CARs and cancers: questions and answers.
abstract: In this issue of Blood, Till et al present 3 patients with relapsed B-cell lymphomas treated with autologous T cells genetically modified to express a CD20-targeted chimeric antigen receptor (CAR) demonstrating both safety and clinical efficacy.
authors.affiliation: Memorial Sloan-Kettering Cancer Center.
authors.forename: Renier J
authors.initials: RJ
authors.lastname: Brentjens